In adults with type 2 diabetes and obesity, bimagrumab increases lean body mass by 3.6% and decreases fat mass, whereas most weight-loss treatments reduce both fat and lean mass.
See the scientific wording
In adults with type 2 diabetes and obesity, administration of bimagrumab increases lean mass by 3.6% and reduces fat mass, a dual effect distinct from typical weight-loss interventions that result in lean mass loss.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
Randomized Controlled TrialHuman2021
In people with type 2 diabetes and extra weight, a drug called bimagrumab helped them gain muscle and lose fat at the same time — which is rare because most diets or exercise programs make you lose muscle along with fat.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a receptor that normally stops muscle growth and keeps fat cells inactive. This allows muscles to get bigger and fat cells to burn more energy, leading to more muscle and less fat at the same time.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with type 2 diabetes and obesity, bimagrumab increases lean body mass by 3.6% and decreases fat mass, whereas most weight-loss treatments reduce both fat and lean mass.
Mechanism
1 studyA drug blocks a natural brake on muscle growth and turns fat cells into energy-burning units. Muscles get bigger, fat gets smaller, and the body burns more calories at rest—all without changing diet or exercise.
A drug blocks a receptor that normally stops muscle growth and keeps fat cells inactive. This allows muscles to get bigger and fat cells to burn more energy, leading to more muscle and less fat at the same time.
Bimagrumab binds to activin type II receptors on skeletal muscle cells and adipocytes, preventing endogenous ligands such as myostatin and activin from activating these receptors
Blockade of activin type II receptor signaling removes inhibition of the Akt/mTOR pathway in skeletal muscle, resulting in increased protein synthesis and muscle fiber hypertrophy
In adipose tissue, activin type II receptor inhibition enhances mitochondrial activity and thermogenic programming, increasing energy expenditure and promoting remodeling of white adipose tissue toward a more metabolically active state
Increased skeletal muscle mass elevates basal metabolic rate, while reduced visceral and hepatic fat decreases ectopic lipid accumulation and improves systemic insulin sensitivity
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
In people with type 2 diabetes and extra weight, a drug called bimagrumab helped them gain muscle and lose fat at the same time — which is rare because most diets or exercise programs make you lose muscle along with fat.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Bimagrumab Effects on Lean and Fat Mass in Adults with Type 2 Diabetes and Obesity
Population: Adults with type 2 diabetes and obesity; Intervention: Bimagrumab; Comparator: Placebo or standard weight-loss intervention; Outcomes: Change in lean mass (kg) and fat mass (kg) measured by DEXA; Duration: Minimum 24 weeks; Inclusion: All published randomized controlled trials with quantitative outcomes.
Double-Blind, Placebo-Controlled Trial of Bimagrumab on Body Composition in Adults with Type 2 Diabetes and Obesity
Population: Adults aged 30–70 with confirmed type 2 diabetes and BMI ≥30; Intervention: Bimagrumab administered intravenously at standard clinical dose; Comparator: Placebo injection; Outcomes: Primary: Change in lean mass (DEXA) and fat mass (DEXA) at 24 weeks; Secondary: Safety, HbA1c, insulin sensitivity; Duration: 24 weeks; Randomization: Stratified by baseline BMI and HbA1c; Blinding: Double-blind.
Prospective Cohort Study of Bimagrumab Use and Body Composition Changes in Real-World Type 2 Diabetes and Obesity Populations
Population: Adults with type 2 diabetes and obesity prescribed bimagrumab in clinical settings; Comparator: Matched adults receiving standard weight-loss care; Outcomes: Change in lean mass and fat mass over 12–48 months; Duration: Minimum 12 months; Data sources: Electronic health records, DEXA scans, lab values; Adjustment: For age, sex, baseline BMI, comorbidities, medication use.
Case-Control Study Comparing Body Composition Outcomes in Adults with Type 2 Diabetes and Obesity Treated with Bimagrumab vs. Those Who Did Not Receive It
Population: Adults with type 2 diabetes and obesity; Cases: Individuals with ≥3.6% lean mass gain and fat mass reduction after bimagrumab; Controls: Individuals with no significant change in body composition after standard care; Exposure: Bimagrumab use confirmed by prescription records; Outcome: Binary classification of body composition change; Duration: Retrospective analysis over 1–3 years; Matching: Age, sex, baseline BMI, HbA1c.
In Vitro Analysis of Bimagrumab Effects on Human Skeletal Muscle and Adipocyte Differentiation and Metabolism
Population: Human primary myoblasts and adipocytes; Intervention: Exposure to bimagrumab at physiological concentrations; Comparator: Untreated cells; Outcomes: Myotube formation, myosin expression, lipid accumulation, gene expression (e.g., myostatin pathway); Duration: 7–21 days; Replication: Minimum triplicate experiments across three donor lines.